T 细胞疗法治疗移植后淋巴组织增生性疾病。
T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
机构信息
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, 1102 Bates Street, Houston, TX 77030, USA.
出版信息
Nat Rev Clin Oncol. 2012 Sep;9(9):510-9. doi: 10.1038/nrclinonc.2012.111. Epub 2012 Jul 17.
Abstract
Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.
摘要
移植后淋巴组织增生性疾病（PTLD）与 Epstein-Barr 病毒（EBV）感染有关，常发生在器官和造血干细胞移植后。这些淋巴组织增生性疾病是肿瘤，通常表达所有潜伏的 EBV 病毒蛋白，因此可以接受基于 T 细胞的免疫治疗，如供者淋巴细胞输注和 EBV 特异性细胞毒性 T 淋巴细胞的过继转移。在这篇综述中，我们描述了目前基于 T 细胞的治疗方法来治疗 PTLD，并描述了提高这种治疗可行性的策略。
相似文献
1
T-cell therapy in the treatment of post-transplant lymphoproliferative disease.T 细胞疗法治疗移植后淋巴组织增生性疾病。
Nat Rev Clin Oncol. 2012 Sep;9(9):510-9. doi: 10.1038/nrclinonc.2012.111. Epub 2012 Jul 17.
2
Non-uniform Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.移植后淋巴组织增生性疾病患者接受供者淋巴细胞输注后，EB 病毒特异性 T 细胞呈非均一性扩增。
Front Immunol. 2019 Oct 29;10:2489. doi: 10.3389/fimmu.2019.02489. eCollection 2019.
3
LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.针对 EBV 相关移植后淋巴组织增生性疾病的 LMP1 特异性细胞毒性 T 细胞治疗。
Int J Hematol. 2020 Jun;111(6):851-857. doi: 10.1007/s12185-020-02844-7. Epub 2020 Mar 11.
4
Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.造血干细胞移植后 EBV 相关移植后淋巴增殖性疾病（PTLD）。
Eur J Haematol. 2018 Sep;101(3):283-290. doi: 10.1111/ejh.13131. Epub 2018 Aug 3.
5
Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.爱泼斯坦-巴尔病毒相关移植后淋巴增殖性疾病的细胞治疗
Best Pract Res Clin Haematol. 2004 Sep;17(3):401-13. doi: 10.1016/j.beha.2004.05.007.
6
Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植中与爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增殖性疾病预防策略
Rev Med Virol. 2020 Jul;30(4):e2108. doi: 10.1002/rmv.2108. Epub 2020 Apr 17.
7
Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.造血干细胞移植后爱泼斯坦-巴尔病毒淋巴增殖性疾病
Curr Opin Hematol. 2014 Nov;21(6):476-81. doi: 10.1097/MOH.0000000000000083.
8
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.塔布雷塞莱珠单抗治疗利妥昔单抗或利妥昔单抗联合化疗失败后发生 EBV 阳性移植后淋巴增殖性疾病的异基因造血干细胞或实体器官移植受者（ALLELE）：一项 3 期、多中心、开放标签试验。
Lancet Oncol. 2024 Mar;25(3):376-387. doi: 10.1016/S1470-2045(23)00649-6. Epub 2024 Jan 31.
9
Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.用于移植后淋巴细胞增生性疾病过继性免疫治疗的爱泼斯坦-巴尔病毒特异性细胞毒性T淋巴细胞
Blood Rev. 2004 Sep;18(3):193-209. doi: 10.1016/j.blre.2003.12.002.
10
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.实体器官移植患者发生移植后淋巴细胞增生性疾病时，爱泼斯坦-巴尔病毒特异性细胞毒性T细胞的激活与过继转移
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10391-6. doi: 10.1073/pnas.96.18.10391.
引用本文的文献
1
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas.EBV相关淋巴瘤患者接受EBVST免疫治疗后对EBV蛋白质组的差异性抗体反应。
Blood Adv. 2025 Apr 8;9(7):1658-1669. doi: 10.1182/bloodadvances.2024014937.
2
A small molecule that selectively inhibits the growth of Epstein-Barr virus-latently infected cancer cells.一种选择性抑制爱泼斯坦-巴尔病毒潜伏感染癌细胞生长的小分子。
iScience. 2024 Jul 25;27(9):110581. doi: 10.1016/j.isci.2024.110581. eCollection 2024 Sep 20.
3
Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.来自第三方或移植供体的病毒特异性T细胞，用于治疗造血细胞或实体器官移植后出现的EBV淋巴增殖性疾病。
Front Immunol. 2024 Jan 11;14:1290059. doi: 10.3389/fimmu.2023.1290059. eCollection 2023.
4
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.利妥昔单抗和第三方 LMP 特异性 T 细胞治疗后对 EBV 的持久免疫力：一项儿童肿瘤学组研究。
Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832.
5
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.同种异体干细胞移植后双特异性 T 细胞预防 CMV/EBV 再激活：来自随机 I/IIa 期 MULTIVIR-01 研究的结果。
Front Immunol. 2023 Oct 30;14:1251593. doi: 10.3389/fimmu.2023.1251593. eCollection 2023.
6
Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.组成型白细胞介素-7 细胞因子信号增强了 EBV 特异性 T 细胞的持久性。
Int J Mol Sci. 2023 Oct 31;24(21):15806. doi: 10.3390/ijms242115806.
7
Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review.病毒特异性 T 细胞疗法治疗中枢神经系统病毒感染：综述。
Viruses. 2023 Jul 6;15(7):1510. doi: 10.3390/v15071510.
8
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.移植后侵袭性 B 细胞淋巴瘤中肿瘤微环境的特征及其临床影响。
Haematologica. 2023 Nov 1;108(11):3044-3057. doi: 10.3324/haematol.2023.282831.
9
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.采用个体化的过继免疫疗法，使用来自亲缘和非亲缘供者的 EBV 特异性 T 细胞。
J Clin Invest. 2023 Jun 15;133(12):e163548. doi: 10.1172/JCI163548.
10
Cross-reactivity influences changes in human influenza A virus and Epstein Barr virus specific CD8 memory T cell receptor alpha and beta repertoires between young and old.交叉反应影响年轻和老年个体之间人类甲型流感病毒和 Epstein Barr 病毒特异性 CD8 记忆 T 细胞受体α和β库的变化。
Front Immunol. 2023 Feb 24;13:1011935. doi: 10.3389/fimmu.2022.1011935. eCollection 2022.
本文引用的文献
1
Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.采用 EBV 核抗原 1 特异性 T 细胞过继转移作为异基因干细胞移植后 EBV 再激活和淋巴增殖性疾病的治疗方法。
J Clin Oncol. 2013 Jan 1;31(1):39-48. doi: 10.1200/JCO.2011.39.8495. Epub 2012 Nov 19.
2
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.快速产生的多种病毒特异性细胞毒性 T 淋巴细胞，用于预防和治疗病毒感染。
Mol Ther. 2012 Aug;20(8):1622-32. doi: 10.1038/mt.2012.130. Epub 2012 Jul 17.
3
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后，采用未经选择或 EBV 特异性 T 细胞进行活检证实的 EBV+淋巴瘤的过继免疫治疗。
Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.
4
Inducible apoptosis as a safety switch for adoptive cell therapy.诱导细胞凋亡作为过继细胞治疗的安全开关。
N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152.
5
Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.将 mTor 抑制剂与雷帕霉素耐药 T 细胞相结合：消除肿瘤的双管齐下策略。
Mol Ther. 2011 Dec;19(12):2239-48. doi: 10.1038/mt.2011.179. Epub 2011 Aug 30.
6
Immune defence against EBV and EBV-associated disease.针对 EBV 及 EBV 相关疾病的免疫防御
Curr Opin Immunol. 2011 Apr;23(2):258-64. doi: 10.1016/j.coi.2010.12.014. Epub 2011 Jan 25.
7
Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation.直接选择的巨细胞病毒反应性供体 T 细胞可在干细胞移植后迅速、安全地重建病毒特异性免疫。
Clin Infect Dis. 2011 Jan 1;52(1):49-57. doi: 10.1093/cid/ciq042.
8
Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation.采用链霉亲和素选择的巨细胞病毒特异性 CD8+ T 细胞过继转移和选择性重建可导致异基因外周血造血干细胞移植后患者的病毒清除。
Transfusion. 2011 Mar;51(3):591-9. doi: 10.1111/j.1537-2995.2010.02940.x. Epub 2010 Dec 6.
9
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.采用第三方 EBV 特异性细胞毒性 T 淋巴细胞对 EBV 相关移植后淋巴瘤进行成功治疗，该患者为脐带血移植后。
Blood. 2010 Dec 2;116(23):5045-9. doi: 10.1182/blood-2010-04-281873. Epub 2010 Sep 8.
10
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.异体 HLA 反应性病毒特异性 T 细胞在人体中不会产生移植物抗宿主病。
Blood. 2010 Nov 25;116(22):4700-2. doi: 10.1182/blood-2010-06-289991. Epub 2010 Aug 13.
Zotero 插件